Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MALT1 | Q9UDY8 | 8/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | RORC | P51449 | 1/20 | 0.40 |
| ▸ | ATR | Q13535 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | MAPKAPK2 | P49137 | 3/20 | 0.39 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.38 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21598682 | 0.83 | RORC (0.47) | MALT1KMT2ARORCLMNASMN1; SMN2 | |
| SCHEMBL31423753 | 0.82 | MAPKAPK2 (0.41) | RORCATRMAPK1MAPKAPK2S1PR3 | |
| SCHEMBL1010435 | 0.80 | ATR (0.46) | RORCATRMAPKAPK2TRPA1 | |
| SCHEMBL23510800 | 0.78 | ALDH1A1 (0.44) | KMT2ARORCATRSMN1; SMN2MAPK1 | |
| SCHEMBL6491966 | 0.78 | MAPKAPK2 (0.47) | RORCATRMAPKAPK2S1PR3 | |
| SCHEMBL18839612 | 0.76 | MAPKAPK2 (0.41) | RORCATRMAPKAPK2 | |
| SCHEMBL29813513 | 0.75 | ATF1 (0.42) | RORCATRMAPKAPK2 | |
| SCHEMBL29813512 | 0.75 | ATF1 (0.42) | RORCATRMAPKAPK2 | |
| SCHEMBL23147986 | 0.75 | ATF1 (0.42) | RORCATRMAPKAPK2 | |
| SCHEMBL25397341 | 0.74 | MAPKAPK2 (0.36) | RORCATRMAPKAPK2S1PR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112601747-B | Pyrazole derivatives as MALT1 inhibitors | 詹森药业有限公司 | 2023-02-21 | — | — | CN | disclosed |
| US-10888550-B2 | Pyrazole derivatives as MALT1 inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2021-01-12 | — | — | US | disclosed |
| WO-2019243965-A1 | PYRAZOLE DERIVATIVES AS MALT1 INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2019-12-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10888550-B2 | Pyrazole derivatives as MALT1 inhibitors | MALT1, PPP3R1, SQSTM1 | MALT1 1/4885KMT2A 3576/4885RORC 1645/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.